Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - octreotide acetate 0.112 mg/ml equivalent to 0.1 mg/ml octreotide base - solution for injection - 0.1 mg/ml - active: octreotide acetate 0.112 mg/ml equivalent to 0.1 mg/ml octreotide base excipient: lactic acid mannitol sodium bicarbonate water for injection

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - octreotide acetate 0.56 mg/ml equivalent to 0.5 mg/ml octreotide base - solution for injection - 0.5 mg/ml - active: octreotide acetate 0.56 mg/ml equivalent to 0.5 mg/ml octreotide base excipient: lactic acid mannitol sodium bicarbonate water for injection

Malta - Englisch - Medicines Authority

novartis pharmaceuticals uk limited - octreotide 0.5 mg/ml - solution for infusion or injection

Malta - Englisch - Medicines Authority

novartis pharmaceuticals uk limited - octreotide 0.2 mg/ml - solution for infusion or injection

Malta - Englisch - Medicines Authority

novartis pharmaceuticals uk limited - octreotide 10 mg - powder and solvent for suspension for injection

Malta - Englisch - Medicines Authority

novartis pharmaceuticals uk limited - octreotide 20 mg - powder and solvent for suspension for injection

Malta - Englisch - Medicines Authority

novartis pharmaceuticals uk limited - octreotide 30 mg - powder and solvent for suspension for injection

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - octreotide -

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - octreotide -

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - octreotide acetate 11.2mg equivalent to octreotide 10 mg;   - powder for injection - 10 mg - active: octreotide acetate 11.2mg equivalent to octreotide 10 mg   excipient: mannitol polyglactin carmellose sodium mannitol poloxamer water for injection carmellose sodium mannitol water for injection - treatment of patients with acromegaly: · in whom surgery or radiotherapy is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective. treatment of patients with symptoms associated with functional gastro-entero-pancreatic endocrine tumours: · carcinoid tumours with features of the carcinoid syndrome. · vipomas · glucagonomas · gastrinomas/zollinger-ellison syndrome · insulinomas, for pre-operative control of hypoglycaemia and for maintenance therapy. · grfomas